PSIL - ETF AI Analysis
Top Page
AdvisorShares Psychedelics ETF (PSIL)
Rating:44Neutral
Price Target:―
Positive Factors
Strong Recent Performance
The ETF has shown strong gains so far this year and over recent months, indicating positive momentum in its niche area.
Top Holdings Showing Solid Gains
Several of the largest positions, including key psychedelic and neuroscience companies, have delivered strong year-to-date performance that supports the fund’s returns.
Focused Exposure to a Single Theme
The heavy tilt toward health care and psychedelics-related companies gives investors targeted exposure to a specific, emerging segment of the market.
Negative Factors
High Expense Ratio
The fund’s expense ratio is relatively high, which means more of the returns are used to cover fees instead of going to investors.
Sector Concentration Risk
With almost all assets in the health care sector, the ETF is highly sensitive to setbacks or regulatory changes affecting this single industry.
Geographic and Holding Concentration
The portfolio is heavily focused on U.S. stocks and a small group of companies, so performance depends strongly on a limited set of names and one country’s market.
PSIL vs. SPDR S&P 500 ETF (SPY)
AUM33.65M
RegionGlobal
Expense Ratio1.00%
Beta0.94
IssuerAdvisorShares
Inception DateSep 15, 2021
Dividend Yield9.19%
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume39,205
30 Day Avg. Volume32,809
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
59.16Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering26
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PSIL Summary
The AdvisorShares Psychedelics ETF (PSIL) is a health care fund focused on companies developing psychedelic-based treatments, mainly in the pharma, biotech, and life sciences space. It does not track a traditional index, but instead targets the theme of mental health innovation, including firms like COMPASS Pathways and Neurocrine. Someone might invest in PSIL if they believe psychedelic medicines could see strong long-term growth and want a diversified way to access this niche area. However, this ETF is very specialized and can be highly volatile, so its price can rise and fall sharply.
How much will it cost me?The AdvisorShares Psychedelics ETF (PSIL) has an expense ratio of 0.99%, meaning you’ll pay $9.90 per year for every $1,000 invested. This is higher than average because it is actively managed, focusing on a specialized niche in the health care sector. Actively managed funds typically have higher costs due to the research and expertise involved in selecting investments.
What would affect this ETF?The AdvisorShares Psychedelics ETF (PSIL) could benefit from increasing acceptance of psychedelics in mainstream medicine and growing investment in mental health treatments, particularly for conditions like depression and PTSD. However, regulatory hurdles, slow drug approval processes, and potential shifts in public perception or government policies could negatively impact the sector’s growth. Global exposure and reliance on innovative but early-stage companies may add both opportunities and risks for investors.
PSIL Top 10 Holdings
PSIL is a high-conviction bet on experimental mental health treatments, with most of its firepower in a handful of small, clinical-stage biotech names. Compass Pathways and atai Life Sciences are doing the heavy lifting lately, both rising on optimism around their psychedelic drug pipelines. Relmada Therapeutics and GH Research are also climbing, adding fuel to the fund’s recent momentum. On the flip side, more traditional neuro players like Neurocrine and Neuronetics look steadier to slightly lagging, acting as ballast. Overall, it’s a global, health-care-heavy portfolio squarely tied to the fate of next‑gen psychedelics.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Atai Beckley N.V. | 10.04% | $3.26M | $1.51B | 114.14% | 47 Neutral | |
| COMPASS Pathways | 9.86% | $3.20M | $1.47B | 150.46% | 47 Neutral | |
| Relmada Therapeutics | 8.81% | $2.86M | $752.06M | 1281.50% | 41 Neutral | |
| Definium Therapeutics | 8.24% | $2.68M | $2.28B | 200.72% | 40 Neutral | |
| GH Research | 6.00% | $1.95M | $1.55B | 91.18% | 45 Neutral | |
| NRX Pharmaceuticals | 5.39% | $1.75M | $107.60M | 12.93% | 45 Neutral | |
| Neurocrine | 5.10% | $1.66M | $15.55B | 29.84% | 80 Outperform | |
| Bright Minds Biosciences | 4.87% | $1.58M | C$1.12B | 151.56% | 48 Neutral | |
| Alto Neuroscience, Inc. | 4.62% | $1.50M | $729.25M | 629.12% | 42 Neutral | |
| Alkermes | 4.51% | $1.46M | $6.16B | 22.96% | 80 Outperform |
PSIL Technical Analysis
Positive
―
Price Trends
18.52
Positive
17.82
Positive
17.28
Positive
Market Momentum
0.34
Positive
59.00
Neutral
54.66
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PSIL, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 20.02, equal to the 50-day MA of 18.52, and equal to the 200-day MA of 17.28, indicating a bullish trend. The MACD of 0.34 indicates Positive momentum. The RSI at 59.00 is Neutral, neither overbought nor oversold. The STOCH value of 54.66 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PSIL.
PSIL Peer Comparison
Comparison Results
Performance Comparison
PSIL
AdvisorShares Psychedelics ETF
20.45
8.88
76.75%
HRTS
Tema Cardiovascular and Metabolic ETF
―
―
―
OZEM
Roundhill GLP-1 & Weight Loss ETF
―
―
―
FMED
Fidelity Disruptive Medicine ETF
―
―
―
MEDI
Harbor Health Care ETF
―
―
―
TMED
T. Rowe Price Health Care ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents